Author(s): Ajay I. Patel, Anjali K. Mandavia, Amit J. Vyas, Ashok B. Patel

Email(s): anjali.mandavia1@gmail.com

DOI: 10.52711/2231-5675.2023.00049   

Address: Ajay I. Patel1, Anjali K. Mandavia1*, Amit J. Vyas1, Ashok B. Patel2
1Pharmaceutical Quality Assurance Department, B. K. Mody Government Pharmacy College, Rajkot, Gujarat, India.
2Government Pharmacy College, Gandhinagar, Gujarat, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 4,     Year - 2023


ABSTRACT:
Nitrosamine impurities have been detected in various pharmaceutical products in recent days. Various sartans, ranitidine, nizatidine and metformin have been recalled from the markets due to the high limit of nitrosamine impurities. When assessing the danger of human cancer, pharmaceutical products ability to regulate potentially mutagenic and carcinogenic contaminants is crucial. The risk of their mutagenic and carcinogenic potential has increased with the recent finding of nitrosamine impurities in various commercially available medications. Nitrosamine is the substance deemed to be a potential human carcinogen by the International Agency for Research on Cancer (IARC). Impurities in nitrosamines have been shown to be mutagenic and carcinogenic; even very low exposure levels to these impurities can cause cancer. These impurities may be created by a reagent, catalyst, solvent, or raw materials employed in the manufacturing process and end up in drug substances or drug products. Angiotensin II receptor blocker (ARB) medications with nitrosamine impurities have caused widespread health problems. Risk management of nitrosamine impurity is necessary to control the level of this impurity in drug substance, drug product and APIs. By using risk management tools like fishbone diagram which is used to identify and organize the possible sources of nitrosamines in medicines. For detection of nitrosamine impurity different countries develops their own analytical methods.


Cite this article:
Ajay I. Patel, Anjali K. Mandavia, Amit J. Vyas, Ashok B. Patel. Nitrosamine Impurity: Management of Unwelcome Guest in Pharma Market. Asian Journal of Pharmaceutical Analysis. 2023; 13(4):303-8. doi: 10.52711/2231-5675.2023.00049

Cite(Electronic):
Ajay I. Patel, Anjali K. Mandavia, Amit J. Vyas, Ashok B. Patel. Nitrosamine Impurity: Management of Unwelcome Guest in Pharma Market. Asian Journal of Pharmaceutical Analysis. 2023; 13(4):303-8. doi: 10.52711/2231-5675.2023.00049   Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-4-13


REFERENCES:
1.    Md. Ahsanul Haque, Mohammad Shahriar, Most. Nazma Parvin, S. M. Ashraful Islam. Validated RP-HPLC Method for Estimation of Ranitidine Hydrochloride, Domperidone and Naproxen in Solid Dosage Form. Asian J. Pharm. Ana. 2011; 1(3): 59-63.
2.    Audumbar Digambar Mali, Patil Manojkumar. Estimation of Ranitidine in Bulk and Formulation by First Order Derivative Area under Curve UV-Spectrophotometry Methods. Asian J. Pharm. Ana. 2015; 5(2): 61-66. doi: 10.5958/2231-5675.2015.00010.1
3.    Rajesh K. Patel, Ravi N. Patel, Dr. Ashok L. Ganure, Laxmanbhai J. Patel. Simultaneous Estimation of Ranitidine and Drotaverine in Combined Pharmaceutical Dosage Form by Derivative Spectrophotometric Method. Asian J. Research Chem. 2012; 5(2): 215-217.
4.    Sonali D. Rathod, P.M. Patil, S. B. Jadhav, P.D. Chaudhari. UV Spectrophotometric Simultaneous Determination of Metformine Hydrochloride and Pioglitazone Hydrochloride in Combined Dosage Form. Asian J. Pharm. Ana. 2012; 2(1): 5-9.
5.    Swapnil D. Jadhav, Akshay A. Magdum, Ramchandra M. Panchal, Pradip S. Koli. Simultaneous Estimation of Metformin Hydrochloride and Rosiglitazone Maleate from Tablet Dosage Form by Derivative Spectroscopic Method. Asian J. Pharm. Ana. 2013; 3(3): 94-97.
6.    JayshreePawar, Sandeep Sonawane, Santosh Chhajed, Sanjay Kshirsagar. Development and Validation of RP-HPLC method for simultaneous Estimation of Metformin HCl and Gliclazide. Asian J. Pharm. Ana. 2016; 6(3): 151-154. doi: 10.5958/2231-5675.2016.00024.7
7.    SouravKhawas, Sampurna Parui, Suddhasattya Dey, Sudip Kr. Mondal, Saptarshy Sarkar. Simultaneous Spectrophotometric Estimation of Rifampicin, Isoniazid and Pyrazinamide in their Pharmaceutical Dosage Form. Asian J. Research Chem. 2020; 13(2): 117-122. doi: 10.5958/0974-4150.2020.00024.3
8.    AM Avachat, SB Bhise. Development and Characterization of a Stable Suspension of Rifampicin and Isoniazid. Research J. Pharma. Dosage Forms and Tech. 2009; 1(3): 213-216.
9.    Satish Balkrishna Bhise, Sevukarajan Mookkan. Poor Bioavailability of Rifampicin- A Global Emergency. Research J. Pharm. and Tech. 2008; 1(3): 155-160.
10.    Risk assessment and mitigation of the presence of nitrosamine impurities in medicines: https://repositorio.ul.pt/bitstream/10451/54117/1/TM_Maria_Ines_Lapo.pdf
11.    Control of Nitrosamine Impurities in Human Drugs Guidance for Industry: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
12.    Tuesuwan B, Vongsutilers V. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control. Journal of Pharmaceutical Sciences. 2021; 110: 3118-3128. https://doi.org/10.1016/j.xphs.2021.04.021
13.    Nitrosamines How to address these unwelcome guests in the pharmaceutical world:  https://www.lachmanconsultants.com/2019/07/how-to-address-nitrosamines-in-the-pharmaceutical-world/
14.    Bharate S. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. Journal of Medicinal Chemistry. 2021; 64: 2923-2936. https://dx.doi.org/10.1021/acs.jmedchem.0c02120?ref=pdf
15.    FDA addresses nitrosamines in TB drugs: https://www.raps.org/news-and-articles/news-articles/
16.    Tabrez Shaikh, Amit Gosar, Hussain Sayyed. Nitrosamine Impurities in Drug Substances and Drug Products. Journal of Advances in Pharmacy Practices. 2020; 2(1): 48–57. http://doi.org/10.5281/zenodo.362909
17.    EMA overview: Lessons learnt from presence of N-nitrosamine impurities in sartan medicines: https://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pd
18.    EMA Assessment report: angiotensin-II-receptor antagonists (sartans) containing a tetrazole group, Referral under Article 31 of Directive 2001/83/EC: https://www.ema.europa.eu/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf
19.    Wagner J, Colombo J. Medicine and Media: The Ranitidine Debate. Clin Transl Sci. 2020; 1–3. doi: https://doi.org/10.1111/cts.12753
20.    https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine
21.    FDA Requests Removal of All Ranitidine Products (Zantac) from the Market: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidineproducts-zantac-mark
22.    NMBA: https://www.caymanchem.com/product/30911/n-nitroso-n-methyl-4-aminobutyric-acid#:~:text=Product%20Description-, N%2DNitroso%2DN%2Dmethyl%2D4%2Daminobutyric%20acid,a%20tobacco%2
23.    U.S. Food and Drug Administration. Updates and press announcements on angiotensin II receptor blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcementsangiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan
24.    Nitrosamine impurities in human medicinal products https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490- assessment-report_en.pdf
25.    Telling G. The determination of N-nitrosamines in foods and cosmetics. Trends in analytical chemistry. 1982; 1 (12).  
26.    Cho I., bratzler L. Effect of sodium nitrite on flavor of cured pork. Ournal of Food Science. 1970; 35.
27.    Jong-eun Park, Jung-eunSeo, Jee-yeon Lee, Hoonjeong Kwon. Distribution of Seven N-Nitrosamines in Food. Toxicological Research. 2015; 31(3): 279-288.
28.    Ling Li, Peng Wang, Xinglian Xu, Guanghong Zhou. Influence of Various Cooking Methods on the Concentrations of Volatile N-Nitrosamines and Biogenic Amines in Dry-Cured Sausages. Journal of Food Science. 2012; 77(5).
29.    Pensabene J, Fiddler W, Gates R, Fagan J, Wassrman A. Effect of frying and other cooking conditions on nitrosopyrrolidine formation in bacon. Journal of Food Science. 1974; 39.
30.    Mitch W, Sharp J, Trussell R, Valentine R, Alvarez-cohen L, Sedlac D. N-Nitrosodimethylamine (NDMA) as a Drinking Water Contaminant: A Review. Environmental Engineering Science. 2003; 20(5).
31.    Gwen C, Woods A, Rebecca A, Trenholm A, Bruce B, Zeke B, Eric V. Dickenson. Seasonal and spatial variability of nitrosamines and their precursor sources at a large-scale urban drinking water system. Science of the Total Environment. 2015; 520: 120– 126. http://dx.doi.org/10.1016/j.scitotenv.2015.03.012
32.    Peter A, Smith S, Richard N, Loeppky. Nitrosative Cleavage of Tertiary Amines. Journal of the American Chemical Society. 1967; 89(5).
33.    Fiddler W, John W, Robert C, Aaron E, Wasserman A. Formation of N-Nitrosodimethylamine from naturally occurring quaternary ammonium compounds and tertiary amines. Nature. 1972; 236.
34.    Gillatt P, Hart R, Walters C. Susceptibilities of drugs to nitrosation under standardized chemical conditions. Fd Chem. Toxic. 1984; 22(4): 269-274.
35.    Sedlo I, Colonic T, Tomic S. Presence of nitrosamine impurities in medicinal product. Sciendo. 2021; 72(1): 1-5. Doi: https://doi.org/10.2478/aiht-2021-72-3491
36.    Nitrosamine impurities: https://www.kpbma.or.kr/api_board/download/seminar/459
37.    FDA issues new guidance on nitrosamine impurities in APIs and Drug products: FDA Issues New Guidance on Nitrosamine Impurities in APIs and Drug Products | Alston & Bird - JDSupra
38.    Shaik K, Sarmah B, Wadekar G, Kumar P. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques. Critical Reviews in Analytical Chemistry. 2020. Doi: https://doi.org/10.1080/10408347.2020.1788375
39.    Vyas A., Godhaniya J., Patel A., Patel A., Patel N., Chudasama A., Shah S. A Review on Carcinogenic Impurities Found in Marketed Drugs and Strategies for its Determination by Analytical Methods. Asian Journal of Pharmaceutical Analysis. 2021, 11(2), 159-169. DOI: 10.52711/2231-5675.2021.00028

Recomonded Articles:

Author(s): Dipti G. Phadtare, Pawar Amol R, R.B. Saudagar

DOI: 10.5958/2231-5675.2016.00019.3         Access: Closed Access Read More

Author(s): Pankaj Bhamare, Rupal Dubey, Neeraj Upmanyu, Pothuvan Umadoss

DOI: 10.5958/2231-5675.2021.00001.6         Access: Open Access Read More

Author(s): Hamid Khan, Javed Ali

DOI: 10.5958/2231-5675.2017.00020.5         Access: Open Access Read More

Author(s): K. Pramod, Shahid H. Ansari, Javed Ali

DOI:         Access: Open Access Read More

Author(s): G. Krishnamoorthy, C. Diana Priyadarshini, R. Senthamarai

DOI:         Access: Open Access Read More

Author(s): Shobha Rani G, Lohita M, Jaya Preethi P, Madhavi R, Sunisitha B, Mounika D

DOI:         Access: Open Access Read More

Author(s): Pinaz A. Kasad, K.S. Muralikrishna

DOI:         Access: Open Access Read More

Author(s): Kirthi A, Shanmugam R, Mohana Lakshmi S , Ashok Kumar CK, Padmini K, Shanti Prathyusha M, Shilpa V

DOI:         Access: Open Access Read More

Author(s): Mansi J. Chaudhari, Suraj R. Chaudhari, Shailesh S. Chalikwar, Atul A. Shirkhedkar

DOI: 10.5958/2231-5675.2018.00008.X         Access: Open Access Read More

Author(s): Khushboo Patel*, Dhara Patel, Jaya Dwivedi, Priyanka Newal, Dhananjay Meshram

DOI: 10.5958/2231-5675.2017.00039.4         Access: Open Access Read More

Author(s): Saroj Kumar Raul, Gopal Krishna Padhy, Pramudula Ramya Krishna, Boddu Uma Madhu Priya

DOI:         Access: Open Access Read More

Author(s): Saroj Kumar Raul, Bukkuru Spandana, Patibandla Sameera, Vegiraju Vikitha

DOI:         Access: Open Access Read More

Asian Journal of Pharmaceutical Analysis (AJPA) is an international, peer-reviewed journal, devoted to pharmaceutical analysis...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5675 


Recent Articles




Tags